List of Excipients in Branded Drug CLEVIPREX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	EDETATE DISODIUM	2031-10-10
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	EGG PHOSPHOLIPIDS	2031-10-10
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	GLYCERIN	2031-10-10
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	OLEIC ACID	2031-10-10
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	SODIUM HYDROXIDE	2031-10-10
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	SOYBEAN OIL	2031-10-10

Cleviprex Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Cleviprex is a clevidipine butyrate intravenous lipid emulsion used for rapid blood-pressure reduction in perioperative and critical-care settings. Its commercial value is linked less to the active ingredient than to the formulation: a ready-to-use, preservative-free emulsion that permits rapid titration and avoids bedside compounding. The main opportunities are generic or follow-on injectable development, improved lipid-emulsion performance, packaging optimization, hospital-use economics, and differentiated products for patients with excipient sensitivities.

What is Cleviprex and which excipients does it contain?

Cleviprex contains clevidipine butyrate at 0.5 mg/mL in a white injectable emulsion. The marketed formulation uses soybean oil, egg phospholipids, glycerin, sodium hydroxide, and water for injection. It contains no antimicrobial preservative.[1]

Component	Function in Cleviprex
Clevidipine butyrate	Dihydropyridine calcium-channel blocker
Soybean oil	Primary lipid phase and solvent
Egg phospholipids	Emulsifier and interfacial stabilizer
Glycerin	Tonicity adjustment
Sodium hydroxide	pH adjustment
Water for injection	Continuous aqueous phase

The formulation is administered through a dedicated intravenous line or a compatible three-way stopcock. It is not intended to be diluted before administration. The label requires aseptic handling and disposal after the specified in-use period following vial puncture.[1]

The excipient profile creates both value and limitations. Soy and egg-derived components support a conventional injectable-emulsion platform, but they create labeling and market-access issues for patients with relevant hypersensitivity or lipid-metabolism restrictions.

How does the Cleviprex formulation affect clinical use?

The formulation supports rapid dose titration. The product is supplied at a concentration of 0.5 mg/mL, allowing clinicians to increase or decrease infusion rates without preparing a fresh solution.[1]

Key formulation-driven properties

Attribute	Commercial or clinical implication
Ready-to-use emulsion	Reduces pharmacy compounding and preparation time
Preservative-free formulation	Limits preservative-related toxicity concerns in intravenous use
0.5 mg/mL concentration	Supports titration but requires relatively high infusion volumes at upper doses
Lipid vehicle	Enables solubilization of poorly water-soluble clevidipine
Single-use handling	Creates waste and raises per-dose acquisition cost
Soy and egg excipients	Restricts use in certain patients and creates differentiation opportunities
White emulsion appearance	Requires control of visible particles, phase separation, and container compatibility

Cleviprex can produce a substantial lipid burden at high infusion rates. At the labeled maximum of 32 mg/hour, the 0.5 mg/mL concentration corresponds to 64 mL/hour of product. Because the emulsion contains approximately 20% soybean oil, this can deliver about 12.8 grams of lipid per hour, subject to the actual product composition and infusion duration.[1]

That relationship creates a formulation trade-off. A more concentrated product could reduce fluid and lipid exposure, but it would require new stability, safety, extractables, compatibility, and clinical bridging work. A 1 mg/mL formulation would cut infusion volume in half but would not automatically qualify as a substitutable product under the same regulatory pathway.

What excipient strategies are available for Cleviprex follow-on products?

The most practical strategies fall into four categories: matching the reference formulation, modifying the lipid phase, replacing animal-derived emulsifiers, and creating a higher-concentration product.

1. Reference-matched soybean oil emulsion

A formulation that closely matches the Cleviprex qualitative and quantitative composition has the lowest technical risk for an ANDA-style development program. The development target would include:

• 0.5 mg/mL clevidipine butyrate.
• Soybean oil as the lipid phase.
• Egg phospholipids as the primary emulsifier.
• Glycerin for tonicity.
• Comparable pH and osmolality.
• Comparable droplet-size distribution.
• Comparable container-closure system.

This approach maximizes the likelihood of pharmaceutical-equivalence arguments and simplifies hospital substitution. Its disadvantages are limited product differentiation and continued exposure to soy and egg excipient concerns.

2. Alternative lipid systems

Alternative oils may improve oxidation stability, reduce dependence on soybean oil, or support a different droplet-size profile. Candidate lipid phases in injectable-emulsion development may include medium-chain triglycerides, olive-oil fractions, fish-oil components, or mixed-oil systems.

Each alternative changes the regulatory burden. The sponsor would need to characterize:

• Mean droplet diameter and distribution.
• Large-diameter tail particles, including PFAT5.
• Zeta potential and emulsion stability.
• Peroxide and aldehyde formation.
• Hydrolysis and degradation products.
• Interaction with clevidipine butyrate.
• Compatibility with infusion sets and pumps.
• Sterilization and terminal-processing effects.

A new lipid system may create a clinically differentiated product, but it reduces the probability of a simple pharmaceutical-equivalence strategy. It may require additional nonclinical or clinical evidence, depending on the extent of formulation change and FDA feedback.

3. Plant-derived or synthetic emulsifiers

Egg phospholipids are central to the reference formulation. A follow-on product could investigate synthetic phospholipids or plant-derived lecithin to address supply, allergen, or quality-consistency concerns.

The commercial rationale is strongest where hospitals have restrictions on egg-derived excipients or where supply-chain resilience matters. The technical challenge is maintaining the interfacial film around the oil droplets while preserving injectability and shelf life.

Synthetic emulsifiers may also create intellectual-property value. Claims could cover:

• Specific phospholipid ratios.
• Mixed phosphatidylcholine and phosphatidylethanolamine systems.
• Defined fatty-acid distributions.
• Emulsion particle-size ranges.
• Stability under refrigerated and room-temperature storage.
• Low-peroxide formulations.
• Container-closure combinations.

Such claims would need meaningful formulation specificity. Broad claims directed only to clevidipine in an injectable emulsion would face greater validity and prior-art risk.

4. Higher-concentration clevidipine emulsions

A 1 mg/mL product could reduce infusion volume, lipid administration, packaging consumption, and disposal. It may be attractive in patients requiring prolonged infusion or in settings where fluid restriction matters.

The principal development issues are:

• Dose-delivery accuracy at low infusion rates.
• Increased risk of local irritation or dosing error.
• Emulsion stability at higher drug loading.
• Pump and tubing compatibility.
• Need for new labeling and administration instructions.
• Whether the product can be substituted for 0.5 mg/mL Cleviprex.

A higher-concentration product is more likely to be a 505(b)(2) or separate NDA opportunity than a directly substitutable ANDA, depending on the final formulation and FDA determination.[2]

What FDA regulatory pathway applies to Cleviprex generic development?

Cleviprex is an approved small-molecule injectable drug. A conventional follow-on product would generally be evaluated through the abbreviated new drug application pathway if it can demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.[2]

Regulatory priorities for a clevidipine emulsion

FDA review of a generic injectable emulsion is likely to focus on:

1. Active-ingredient identity and strength.
2. Dosage form and route of administration.
3. Qualitative and quantitative excipient composition.
4. Droplet-size distribution and emulsion attributes.
5. Sterility and bacterial endotoxin limits.
6. Particulate matter.
7. Stability and in-use dating.
8. Container-closure integrity.
9. Extractables and leachables.
10. Product performance through the proposed administration system.

For a complex injectable emulsion, conventional analytical comparability is more demanding than simple assay and dissolution testing. The product must remain physically stable throughout manufacture, shipping, storage, and administration. Phase separation, coalescence, creaming, drug precipitation, and large-droplet formation can affect both safety and regulatory acceptance.

What patents protect Cleviprex and its formulation?

The commercial patent analysis should separate four categories:

Patent category	Relevance to Cleviprex
Clevidipine compound patents	Historically protected the active pharmaceutical ingredient
Composition-of-matter patents	May cover clevidipine butyrate or related prodrug forms
Formulation patents	May cover lipid emulsions, excipient ratios, particle size, or stability
Method-of-use patents	May cover perioperative hypertension, acute blood-pressure control, or dosing methods

Cleviprex received FDA approval under NDA 022156 in 2008.[1] Its five-year new chemical entity exclusivity period would have run from approval and is no longer a current barrier. The relevant present-day questions are Orange Book-listed patents, any pediatric exclusivity, and the status of listed formulation or method-of-use claims.[2][3]

A sponsor evaluating an ANDA would need to review:

• Current Orange Book patent listings for NDA 022156.
• Patent-use codes associated with any listed method-of-use patents.
• Patent term adjustments and extensions.
• Paragraph IV certification exposure.
• Federal district-court litigation under the Hatch-Waxman framework.
• Any FDA-approved labeling carve-outs.
• Patent assignments, licenses, and terminal disclaimers.

No commercial strategy should assume that expiration of the core clevidipine compound patent eliminates all risk. Formulation and manufacturing patents can remain relevant after composition-of-matter protection ends. Conversely, formulation patents may have limited blocking value if a generic can use a materially different excipient system.

When does Cleviprex lose exclusivity and face generic competition?

Cleviprex’s original regulatory exclusivity has expired. Generic-entry timing therefore depends primarily on listed patent barriers, FDA review, manufacturing readiness, and litigation outcomes rather than on remaining new chemical entity exclusivity.[1][2]

Generic launch scenarios

Scenario	Likely commercial effect
No blocking patent remains	Earliest market entry after FDA approval and product launch readiness
Paragraph IV challenge with no injunction	Potential launch before patent expiry, subject to litigation
30-month stay after Paragraph IV litigation	Delayed approval or launch unless litigation resolves earlier
Authorized generic or licensed launch	Faster hospital conversion and lower legal risk
Formulation-specific patent survives	Alternative excipient product may launch while a matching product remains blocked
Manufacturing patent remains enforceable	Supply-chain design and process changes become necessary

Cleviprex is a small-molecule product, so biosimilar risk is not the relevant competitive framework. The principal threats are ANDA products, authorized generics, 505(b)(2) reformulations, and hospital protocols that substitute other intravenous antihypertensives.

Which companies are positioned to challenge Cleviprex?

The most credible competitors are manufacturers with established sterile injectable capabilities, lipid-emulsion manufacturing, and hospital distribution. Relevant categories include:

• Large generic companies with injectable portfolios.
• Contract development and manufacturing organizations with aseptic emulsion capacity.
• Hospital-focused specialty pharmaceutical companies.
• Firms with existing products in critical-care cardiovascular therapy.
• Regional manufacturers seeking U.S. injectable entry.

The technical barrier is higher than for a standard aqueous injectable. A sponsor must have validated emulsion production, high-shear mixing or equivalent process capability, sterile filtration or terminal sterilization expertise, and appropriate control of subvisible particles.

A company with only conventional vial-filling capacity may need a development or manufacturing license. That creates licensing opportunities around:

• Clevidipine formulation know-how.
• Lipid-emulsion process parameters.
• Ready-to-use vial manufacturing.
• Prefilled syringe or bag presentation.
• Analytical methods for emulsion comparability.
• U.S. ANDA ownership and commercialization.

What commercial opportunities exist for Cleviprex excipient innovation?

Hospital cost reduction

A lower-cost generic can compete on acquisition price, but hospitals also value:

• Reduced pharmacy preparation.
• Lower nursing handling time.
• Reliable supply.
• Clear titration instructions.
• Compatibility with automated infusion pumps.
• Reduced product waste.
• Consistent availability during perioperative demand spikes.

A product with a longer in-use period, if supported by stability data and accepted in labeling, could reduce wastage. A multidose presentation could improve utilization but would create sterility and preservative questions. A preservative-free single-use product remains the lower-risk hospital standard.

Alternative presentations

Potential presentations include:

Presentation	Opportunity
50 mL vial	Closest to current hospital workflow
100 mL vial	Lower handling frequency for prolonged infusions
Ready-to-use infusion bag	Removes vial transfer and may reduce setup time
Prefilled syringe	Potential use in operating rooms and emergency settings
1 mg/mL concentration	Reduces fluid volume but requires new regulatory and clinical positioning
Dual-source private-label product	Supports group purchasing and health-system contracting

The container must preserve emulsion integrity and avoid adsorption or leaching. Plastic bags, elastomeric closures, and syringe materials can change the drug’s stability profile and require dedicated studies.

Supply-chain differentiation

Soybean oil and egg phospholipids are established excipients but remain subject to agricultural supply, quality, and allergen-management considerations. A sponsor that qualifies multiple suppliers or develops a synthetic-phospholipid alternative could market supply resilience to hospitals and distributors.

The strongest supply-chain claims would be supported by:

• Dual-source excipient qualification.
• Defined impurity specifications.
• Low-peroxide raw materials.
• Long-term stability data.
• Validated cold-chain or controlled-room-temperature storage.
• Multiple fill-finish sites.

How does Cleviprex compare with nicardipine and other intravenous antihypertensives?

Cleviprex competes mainly with intravenous nicardipine, labetalol, esmolol, nitroprusside, and hydralazine. The choice depends on onset, titratability, adverse-effect profile, clinical setting, and pharmacy workflow.

Product	Formulation consideration	Commercial implication
Cleviprex	Lipid emulsion; ready to use	Fast titration, but higher formulation complexity
Nicardipine injection	Aqueous concentrate or premixed presentations	Broader generic availability and lower technical barrier
Labetalol injection	Aqueous solution	Competes in acute-care protocols
Esmolol injection	Aqueous solution or premix	Stronger fit where heart-rate control is also required
Nitroprusside	Aqueous solution with light sensitivity	Different monitoring and handling requirements
Hydralazine	Aqueous injectable	Lower-cost alternative but less predictable titration

Cleviprex’s strongest commercial position is in settings that prioritize rapid titration and ready-to-use administration. Its weakest position is in price-sensitive formularies where nicardipine or labetalol offers adequate clinical performance at lower acquisition cost.

What formulation patents could create defensible commercial value?

A defensible patent estate would focus on measurable technical features rather than the general concept of using clevidipine in an emulsion.

Potential claim areas include:

H3: What emulsion characteristics are patentable?

• Defined mean droplet diameter.
• Narrow particle-size distribution.
• Upper limits for large-diameter droplets.
• Specific phospholipid-to-oil ratios.
• Low peroxide or oxidative-degradation levels.
• Stability after agitation, freezing excursions, or prolonged storage.
• Defined pH and osmolality ranges.
• Reduced adsorption to infusion tubing.
• Compatibility with specific pump systems.

H3: What manufacturing methods may be protected?

• Order of excipient addition.
• Homogenization pressure and cycle number.
• Temperature-controlled drug incorporation.
• Nitrogen-overlay processing.
• Sterilization conditions.
• In-process particle-size controls.
• Aseptic filling under defined oxygen-exposure limits.

Manufacturing patents can create practical barriers even when a competitor avoids the composition claims. Their value depends on whether the process is visible, necessary, and difficult to design around.

What generic entry risks exist for Cleviprex?

The main risks are formulation mismatch, manufacturing scale-up, product-quality observations, and limited hospital uptake after approval.

A technically viable generic must establish more than clevidipine assay and sterility. It must show that the emulsion remains stable and clinically usable across the proposed shelf life. FDA may scrutinize differences in excipient source, particle-size distribution, container closure, and administration compatibility.

Commercial risks include:

• Low volume relative to broader hospital injectables.
• Existing clinical familiarity with alternative products.
• Group-purchasing pressure.
• Contract-manufacturing dependence.
• High cost of emulsion quality control.
• Product waste from single-use packaging.
• Limited differentiation for a composition-matched generic.

The best entry strategy is usually a staged program: first pursue a reference-matched 0.5 mg/mL product, then develop a differentiated concentration or excipient platform after establishing market access.

What is the revenue exposure and market opportunity?

Cleviprex revenue is concentrated in acute-care institutions rather than chronic outpatient use. Demand is driven by operating rooms, intensive-care units, emergency departments, stroke centers, and postoperative blood-pressure protocols.

Revenue exposure depends on:

• Number of treated admissions.
• Average infusion duration.
• Dose intensity.
• Hospital formulary placement.
• Generic discounting.
• Availability of competing intravenous antihypertensives.
• Supply reliability.
• Contracting with group purchasing organizations.

A generic entrant can capture share without displacing every Cleviprex use. Hospitals may retain the originator for selected protocols while using a lower-cost generic for routine infusions. A differentiated product with lower volume, improved storage, or alternative excipients could command a premium if it produces measurable workflow or patient-selection benefits.

Key Takeaways

• Cleviprex is a clevidipine butyrate lipid emulsion containing soybean oil, egg phospholipids, glycerin, sodium hydroxide, and water for injection.
• The formulation, not the active ingredient alone, creates the product’s clinical and commercial differentiation.
• The lowest-risk generic strategy is a composition-matched 0.5 mg/mL injectable emulsion.
• Higher-concentration products, alternative oils, synthetic phospholipids, bags, and prefilled syringes offer greater differentiation but carry higher regulatory risk.
• Generic competition is governed primarily by Orange Book patents, Paragraph IV activity, FDA review, and manufacturing readiness.
• Cleviprex has no biosimilar exposure because clevidipine is a small molecule.
• The most valuable formulation patents would claim particle-size control, excipient ratios, oxidative stability, packaging, or manufacturing parameters.
• Hospital opportunities center on lower acquisition cost, reduced preparation burden, reliable supply, lower waste, and improved fluid management.
• A reference-matched generic followed by a differentiated formulation is the most practical commercial sequence.

FAQs

Can Cleviprex be reformulated without soybean oil?

Yes, but replacing soybean oil would create a materially different injectable-emulsion product. The sponsor would need to establish stability, safety, emulsion comparability, compatibility, and an appropriate FDA regulatory pathway.

Is Cleviprex suitable for a preservative-containing formulation?

A preservative-containing intravenous product would face substantial clinical and regulatory scrutiny. The current product is preservative-free, and any preservative would require justification for safety, compatibility, sterility strategy, and labeling.

Could a Cleviprex generic use a prefilled syringe?

Potentially. A prefilled syringe could reduce setup time in operating rooms and emergency departments, but the sponsor would need to validate syringe-material compatibility, dose accuracy, emulsion stability, device performance, and extractables and leachables.

Does a different excipient composition automatically avoid Cleviprex patents?

No. Patent scope depends on the issued claims. A different oil or emulsifier may avoid a narrow composition claim but could remain exposed to method, manufacturing, particle-size, or use claims.

What is the strongest commercial differentiator for a new clevidipine product?

The strongest differentiators are likely reduced infusion volume, improved storage or in-use stability, lower waste, supply-chain resilience, and a formulation that reduces dependence on egg- or soybean-derived excipients.

References

1. Chiesi USA, Inc. (2023). Cleviprex (clevidipine butyrate injectable emulsion) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, NDA 022156. https://www.accessdata.fda.gov/scripts/cder/daf/